<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15075">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02063308</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000581</org_study_id>
    <nct_id>NCT02063308</nct_id>
  </id_info>
  <brief_title>Oxaloacetate Pharmacokinetics and Safety</brief_title>
  <official_title>Oxaloacetate Pharmacokinetics and Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Russell Swerdlow, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      By doing this study, researchers hope to learn how much oxaloacetate (OAA) ends up in the
      blood after OAA capsules are swallowed, and to assess whether persons with Alzheimer's
      disease who take OAA for one month have any side-effects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Correlation between oral OAA intake and plasma levels</measure>
    <time_frame>Change from dose to 30, 45, 60, 75, 90, 105, 120, 135, 150, and 240 minutes after dosing</time_frame>
    <safety_issue>No</safety_issue>
    <description>Baseline blood sample will be obtained before 100 mg OAA is administered. Blood samples to be drawn every 15 minutes starting 30 minutes after OAA administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety of OAA in study participants</measure>
    <time_frame>Change from Baseline to Month 1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>We will evaluate weights, blood counts, electrolytes, liver function tests, insulin levels, and plasma amino acid levels in subjects exposed to OAA for 1 month. These multiple measures will be used to generate a composite safety outcome measure.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Oxaloacetate (OAA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg OAA to be taken twice daily over the course of a month</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oxaloacetate (OAA)</intervention_name>
    <arm_group_label>Oxaloacetate (OAA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet criteria for Mild or Moderate AD

          -  Have a study partner

          -  Speak English as primary language.

        Exclusion Criteria:

          -  Absence of a study partner

          -  Report a potentially confounding, serious medical risk such as type 1 diabetes,
             cancer, or a recent cardiac event (i.e. heart attack, angioplasty, etc.)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Russell Swerdlow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca Bothwell, MS</last_name>
    <phone>(913) 945-5033</phone>
    <email>rbothwell@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 13, 2014</lastchanged_date>
  <firstreceived_date>February 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center Research Institute</investigator_affiliation>
    <investigator_full_name>Russell Swerdlow, MD</investigator_full_name>
    <investigator_title>Gene and Marge Sweeney Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Oxaloacetate</keyword>
  <keyword>OAA</keyword>
  <keyword>AD</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
